Omeben 20 mg (Capsule (Enteric Coated))

Unit Price: ৳ 5.00 (10 x 10: ৳ 500.00)

Strip Price: ৳ 50.00

Medicine Details

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

20 mg once daily for benign gastric and duodenal ulcer for 4 weeks in duodenal ulceration
40 mg daily for severe or recurrent cases of benign gastric and duodenal ulcer
20 mg once daily for NSAID-associated duodenal or gastric ulcer for 4 weeks
20 mg once daily for prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
20 mg once daily for gastro-esophageal reflux disease for 4 weeks
40 mg once daily for refractory cases of gastro-esophageal reflux disease
10-20 mg daily for long-term management of acid reflux disease
10-20 mg once daily for acid-related dyspepsia for 2-4 weeks
40 mg for prophylaxis of acid aspiration before surgery
60 mg once daily for Zollinger-Ellison syndrome, with a usual range of 20-120 mg daily
20 mg twice daily in H. pylori eradication regimen in peptic ulcer disease
10-20 mg once daily for severe ulcerating reflux esophagitis in children >1 year
40 mg intravenous injection for prophylaxis of acid aspiration before surgery
40 mg intravenous injection for duodenal ulcer, gastric ulcer, or reflux esophagitis in patients for whom oral medication is inappropriate
60 mg daily intravenously for Zollinger-Ellison syndrome, with higher daily doses if required

Decreased intragastric acidity may reduce absorption of ketoconazole
Metabolized in the liver through cytochrome P450
May delay the elimination of diazepam, phenytoin, and warfarin
Monitoring and potential dose reduction for warfarin or phenytoin
Absorption and plasma concentrations increased during concomitant administration with clarithromycin
No evidence of interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin, or antacids
No affected absorption by alcohol or food
No evidence of interaction with piroxicam, diclofenac, or naproxen
Simultaneous treatment with digoxin may lead to a 10% increase in the bioavailability of digoxin

Mild and reversible adverse reactions
Skin rash, urticaria, pruritus, photosensitivity, bullous eruption, erythema multiforme, angioedema, alopecia
Diarrhoea and headache, with severe cases necessitating therapy discontinuation
Gastrointestinal reactions including constipation, nausea/vomiting, flatulence, abdominal pain
Dry mouth, stomatitis, candidiasis, paraesthesia
Dizziness, light headedness, feeling faint, somnolence, insomnia, vertigo
Reversible mental confusion, agitation, depression, hallucinations
Arthritic and myalgic symptoms, blurred vision, taste disturbance
Peripheral oedema, increased sweating, gynaecomastia
Leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, anaphylactic shock
Malaise, fever, bronchospasm, encephalopathy in patients with pre-existing severe liver disease
Hepatitis with or without jaundice, interstitial nephritis, hepatic failure
Increases in liver enzymes

No adverse effects on pregnancy or fetus/newborn child based on prospective epidemiological studies
Considered safe to use during pregnancy
No available information on the passage of omeprazole into breast milk or its effects on the neonate
Breast-feeding should be discontinued if essential use of omeprazole is considered
Safety and effectiveness not established in pediatric patients less than 18 years of age

Avoid concomitant use with clopidogrel
Observational association with increased risk for osteoporosis-related fractures
Atrophic gastritis noted occasionally in patients treated long-term with omeprazole
Concomitant use with methotrexate may lead to methotrexate toxicities